Neurology diagnostics is one of the areas where AI investment and AI deployment are furthest apart. The research pipeline is full — thousands of papers claiming high accuracy on Alzheimer's detection, stroke identification, Parkinson's progression monitoring, seizure prediction. Actual clinical deployment is considerably thinner. Understanding what's genuinely running in hospitals, what's in trials, and what remains firmly in research labs is useful if you're evaluating where to build or invest.
I've worked on several health-tech projects involving neurological data pipelines, and the gap between published benchmarks and real-world clinical utility is one of the recurring themes. This piece tries to map the landscape honestly.
What's Actually Deployed
A handful of AI neurology tools have cleared regulatory hurdles and entered regular clinical use. These are the real cases:
Automated MRI Segmentation
Tools like FreeSurfer and its cloud-successors, Brainomix e-Stroke, and Viz.ai's stroke detection pipeline are running in real clinical environments. They segment brain structures from MRI automatically, flag potential stroke findings for radiologist review, and quantify lesion volumes. Viz.ai holds FDA clearance and is deployed in hundreds of US hospitals. The clinical value proposition here is speed — flagging a large vessel occlusion in minutes rather than waiting for a radiologist call at 2am — not replacing the radiologist.
Automated EEG Analysis for ICU Monitoring
Natus, Persyst, and Nihon Kohden have deployed FDA-cleared EEG analysis tools that run continuously on ICU patients and flag seizure-like patterns. These are seizure detection tools, not prediction tools — they identify events as they happen, alerting nursing staff when manual monitoring would miss events. In high-acuity settings like neurology ICUs, this is genuinely useful and well-validated. The accuracy is good enough for clinical use as a screening tool, with physician confirmation required.
Retinal Imaging for Neurological Screening
This one is less obvious but arguably the most mature. The retina is neural tissue — an outgrowth of the brain — and retinal vessels reflect systemic vascular and neural health. IDx-DR (now Eyenuk) and Google's retinal AI have FDA clearance for diabetic retinopathy screening and are in clinical use. More recent work shows retinal imaging can detect early Alzheimer's biomarkers and Parkinson's risk. The pipeline here is working: non-invasive, cheap acquisition, high-throughput automated analysis.
What's in Trials and Late-Stage Development
Alzheimer's Biomarker Detection from Blood and CSF
Blood-based biomarkers for Alzheimer's (plasma p-tau 217, amyloid beta ratios) have made substantial progress. Companies like C2N Diagnostics and ALZpath have CE-marked and/or FDA-authorized blood tests. AI plays a supporting role in the analysis pipeline. The story here is the biomarker discovery more than the AI — the machine learning adds value for combining multiple biomarkers and adjusting for confounders, but isn't the core innovation.
Pre-ictal Seizure Prediction from Wearables
Several groups have published promising results for predicting seizures 10–30 minutes in advance using wearable EEG, ECG, or accelerometry combined with personalized machine learning models. Empatica's Embrace2 detects convulsive seizures reliably. True prediction — generating an alert before seizure onset — is harder. The main challenges are class imbalance (seizures are rare events), inter-subject variability requiring per-patient calibration, and false alarm rates that make wearable devices impractical in daily life. There are clinical trials running, but this isn't deployed broadly.
What's Still Research — Despite Press Coverage
Early Alzheimer's Diagnosis from Cognitive and Imaging Data
There are hundreds of papers claiming 85–95% accuracy for early Alzheimer's classification from MRI or cognitive tests. Most of these use small, highly curated datasets (ADNI being common), compare against relatively simple baselines, and have never been validated on prospective data from a real clinical workflow. The clinical question isn't "can the model classify AD vs. controls in a clean research dataset" — it's "does this tool improve diagnostic accuracy or speed in a real hospital setting for a real mix of patients." That validation is largely missing.
Depression and Anxiety Diagnosis from EEG
Quantitative EEG (qEEG) as a psychiatric diagnostic tool has been studied for decades with inconsistent results. Machine learning has not yet resolved the fundamental issue: EEG biomarkers for depression and anxiety are highly heterogeneous, have substantial overlap with other conditions, and don't cleanly map onto current diagnostic categories. Several companies have regulatory clearance for adjunctive qEEG biomarkers in treatment selection (not diagnosis), which is a more limited and defensible claim.
Natural Language Processing for Dementia Screening
Speech and language patterns change measurably in early dementia. NLP models trained on speech samples can classify MCI and early AD with moderate accuracy in research settings. This is genuinely interesting and the data collection method (recording a picture description task) is simple. But performance drops substantially in diverse populations, different languages, and real clinical noise conditions. It's a promising direction that needs more rigorous prospective trials.
Why the Clinical Translation Gap Persists
The persistent gap between research performance and clinical deployment comes down to several structural problems that don't appear in benchmark papers.
Dataset shift is the first. Research datasets are collected under controlled conditions from selected populations. Clinical data is noisier, collected on different hardware, from more diverse populations with more comorbidities. A model trained on ADNI MRI data may perform poorly on data from a different scanner, with different acquisition parameters, from a different population. Shift is pervasive and rarely adequately tested in published work.
Regulatory pathways add significant lead time and cost. FDA 510(k) clearance for a software-only medical device typically takes 6–12 months minimum and requires specific clinical evidence. CE marking in Europe has different requirements. Getting a model from research to regulatory clearance to hospital purchasing to clinical workflow integration often takes 5–7 years and millions of dollars — even if the model itself is excellent.
The clinical workflow integration problem is underappreciated. A model that achieves high accuracy on held-out test data still needs to fit into clinical practice: it needs to produce outputs in a format clinicians trust and can act on, it needs to handle cases where the model is uncertain, it needs to integrate with EHR systems, and it needs clinical champions who will advocate for changing workflows. All of this is harder than building the model.
At Neurivvy Intelligenx, our health-tech R&D work prioritises regulatory-pathway awareness from the start — building to FDA SaMD guidelines and HL7/FHIR data standards rather than retrofitting them later. Projects that don't account for clinical translation early rarely survive the gap.
Where to Expect Real Progress
The areas most likely to produce genuinely deployed clinical AI in neurology over the next three to five years are those where the data is high-quality and structured, the clinical question is specific and binary, and there's a clear workflow slot for an automated assistant. Radiology AI fits all three. Continuous ICU monitoring fits well. Wearable seizure detection for high-risk patients fits reasonably. Diagnostic AI for complex neuropsychiatric conditions fits poorly, at least for now.
The areas requiring most caution are those where published accuracy numbers look impressive but the underlying data quality and population diversity haven't been tested — and where the claims being made go beyond "aids clinical decision-making" toward "diagnoses independently." The former is approvable and defensible. The latter will face very high bars, appropriately.